Is Abogen profitable in 2026?

No. Abogen is a pre-revenue, clinical-stage mRNA biotech with no approved products generating recurring revenue as of mid-2026. Its only authorized product, the ARCoV COVID vaccine (Indonesia EUA, September 2022), saw weak real-world uptake, and the company survives on venture funding raised through November 2021.

Who owns Abogen Biosciences?

Abogen is privately owned and venture-backed, founded in 2019 by Dr. Bo Ying, a former Moderna scientist. Investors include Temasek Holdings, GL Ventures, SoftBank Vision Fund, and Mirae Asset, who backed a combined $1B in Series C and C-II rounds in August and November 2021. No IPO or acquisition has occurred.

Could AI replace Abogen's mRNA drug development?

AI can accelerate parts of Abogen's work, such as mRNA sequence design and ionizable-lipid screening, both of which are commoditizing industry-wide per a Nature Communications study (December 2024). But it cannot replicate Abogen's Phase III clinical data, multi-jurisdiction regulatory dossiers, or GMP manufacturing know-how built from its ARCoV program.

Who is Abogen's biggest competitor?

Domestically, Abogen competes with Stemirna Therapeutics, Walvax Biotechnology, CSPC Pharmaceutical, and RNAimmune, all facing similar Chinese mRNA commercialization struggles reported April 2024. Globally, Moderna and BioNTech dominate approved mRNA products but are structurally barred from the Chinese market by regulation and geopolitics.

What is Abogen's most advanced pipeline product?

Abogen's ABO1108, a lyophilized shingles mRNA vaccine, entered an 18,000-participant Phase III trial (CTR20262350) registered in June 2026, reportedly the first mRNA shingles vaccine globally to reach that stage, per CBInsights (June 2026).

How much money has Abogen raised in total?

Abogen has raised roughly $1.13 to $1.134 billion across about five to six rounds, according to CBInsights (November 2021). This includes a $700M Series C in August 2021 led by Temasek and GL Ventures, and a $300M Series C-II in November 2021 led by SoftBank Vision Fund and Mirae Asset.

China · China

Abogen

Chinese clinical-stage mRNA biotech with one weak-selling COVID shot and a shingles bet.

Losing its protection

Assessed 29 July 2026 · Evidence as of 29 July 2026

The structural protection is eroding.

On the recordSince 29 July 2026 · Checkable from H2 2027 · Every call on the record Checkpoint: ABO1108 shingles vaccine Phase III readout (18,000-subject trial)

The call

Abogen sits on real China-specific protection but no revenue, no fresh cash since 2021, and everything riding on one shingles trial.

Abogen makes messenger RNA vaccines using technology it developed in-house, focused on markets where Western competitors like Moderna and BioNTech are blocked by government rules. Its one approved product, a COVID vaccine in Indonesia, barely sold, and the company has not raised money since late 2021 despite burning cash on large clinical trials. The company is not easy to replace because it owns its own manufacturing facilities and has years of test data that rivals cannot quickly copy, but AI tools for designing mRNA sequences are now widely available to everyone. Everything hinges on whether a large trial testing a shingles vaccine works as hoped (results due sometime between 2027 and 2028), because without that success or fresh funding, the company simply runs out of money to operate.

Why

AI pressure: Generative mRNA sequence and lipid-design AI tools now used industry-wide. AI speeds up sequence and lipid design for everyone, so Abogen's early tech edge in mRNA design keeps shrinking. Could AI do the core job? Only partly.

Bigger players: Moderna and BioNTech. Both are kept out of China by regulation, so they cannot directly take Abogen's home market for now. Could a giant copy it? Probably.

What protects it. China bars foreign mRNA rivals from its market, and Abogen holds its own LNP IP, dossiers, and GMP plant.

What would change this call

ABO1108 shingles Phase III readout (18,000-subject trial, expected 2027-28) is announced. Shows whether Abogen's core pipeline bet, needed to justify its valuation, actually works.
Abogen announces a new equity financing round or IPO filing by end of 2027. Shows whether investors still believe in the company after no funding since Nov 2021.
Stemirna or CSPC Pharmaceutical announces a commercial launch or licensing deal for an mRNA product. Shows a Chinese peer converting mRNA tech into revenue before Abogen does.

Key numbers

$3.70B valuation (2024-11-18)
~$1.13B total funding raised (2021-11-28)
No new financing round since Nov 2021 (2026-06-16)

Named risks

No new financing raised since November 2021 despite high Phase III and manufacturing burn. Severity: high
Entire company valuation binary on ABO1108 shingles Phase III readout within 12 to 24 months. Severity: high
Weak real-world domestic uptake of prior COVID mRNA vaccine signals commercialization risk for future launches. Severity: medium
US mRNA funding wind-down (BARDA cancellations, August 2025) threatens US regulatory and clinical ambitions. Severity: medium
AI-driven mRNA design and lipid screening tools are commoditizing, eroding Abogen's technical differentiation over time. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Moderna and BioNTech	contesting	Structurally barred from China market by geopolitics/regulation as of 2026, limiting direct overlap with Abogen
Stemirna Therapeutics	contesting	Faces similar Chinese mRNA commercialization struggles, per Reuters report April 19, 2024
Walvax Biotechnology	contesting	Original ARCoV manufacturing partner, also struggling with domestic mRNA vaccine demand as of April 2024
CSPC Pharmaceutical Group	contesting	Chinese mRNA peer facing manufacturing and demand setbacks, per April 2024 reporting
BioNTech	losing to	BioNTech's acquisition of CureVac's mRNA cancer business signals consolidation pressure on smaller mRNA players, per 2026 patent report

Questions people ask

Is Abogen profitable in 2026?: No. Abogen is a pre-revenue, clinical-stage mRNA biotech with no approved products generating recurring revenue as of mid-2026. Its only authorized product, the ARCoV COVID vaccine (Indonesia EUA, September 2022), saw weak real-world uptake, and the company survives on venture funding raised through November 2021.
Who owns Abogen Biosciences?: Abogen is privately owned and venture-backed, founded in 2019 by Dr. Bo Ying, a former Moderna scientist. Investors include Temasek Holdings, GL Ventures, SoftBank Vision Fund, and Mirae Asset, who backed a combined $1B in Series C and C-II rounds in August and November 2021. No IPO or acquisition has occurred.
Could AI replace Abogen's mRNA drug development?: AI can accelerate parts of Abogen's work, such as mRNA sequence design and ionizable-lipid screening, both of which are commoditizing industry-wide per a Nature Communications study (December 2024). But it cannot replicate Abogen's Phase III clinical data, multi-jurisdiction regulatory dossiers, or GMP manufacturing know-how built from its ARCoV program.
Who is Abogen's biggest competitor?: Domestically, Abogen competes with Stemirna Therapeutics, Walvax Biotechnology, CSPC Pharmaceutical, and RNAimmune, all facing similar Chinese mRNA commercialization struggles reported April 2024. Globally, Moderna and BioNTech dominate approved mRNA products but are structurally barred from the Chinese market by regulation and geopolitics.
What is Abogen's most advanced pipeline product?: Abogen's ABO1108, a lyophilized shingles mRNA vaccine, entered an 18,000-participant Phase III trial (CTR20262350) registered in June 2026, reportedly the first mRNA shingles vaccine globally to reach that stage, per CBInsights (June 2026).
How much money has Abogen raised in total?: Abogen has raised roughly $1.13 to $1.134 billion across about five to six rounds, according to CBInsights (November 2021). This includes a $700M Series C in August 2021 led by Temasek and GL Ventures, and a $300M Series C-II in November 2021 led by SoftBank Vision Fund and Mirae Asset.

Timeline

2026-06Registered Phase III trial CTR20262350 for shingles vaccine ABO1108, targeting 18,000 subjects
2026-04Presented first-in-human data for ABO2203 T-cell engager at AACR 2026 in B-cell lymphoma patients
2025-08HHS/BARDA cancelled about $500M in mRNA vaccine contracts, signaling US mRNA funding wind-down
2025Received IND approvals in China and the US for KRAS mRNA cancer vaccine candidate ABO2102
2024-08Published novel cis-splicing system for circular RNA production in Nucleic Acids Research
2024-04Reuters reported weak domestic uptake of Chinese mRNA COVID vaccines including Abogen's
2022-09ARCoV COVID vaccine received Emergency Use Authorization in Indonesia, first China-made mRNA vaccine authorized anywhere
2021-11Closed $300M Series C-II led by SoftBank Vision Fund and Mirae Asset
2021-08Closed $700M Series C led by Temasek Holdings and GL Ventures
2019Abogen founded by Dr. Bo Ying, former Moderna scientist

Revision history

29 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Meituan Shein Group Xiaomi Corporation